Cargando…

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Farah, McLaughlin, Taryn, Mesquita, Pedro, Morin, Josee, Potvin, Diane, De Chantal, Marilyn, Aberg, Judith A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947601/ https://www.ncbi.nlm.nih.gov/pubmed/36845310 http://dx.doi.org/10.1017/cts.2022.515

Ejemplares similares

935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial
por: Rahman, Farah, et al.
Publicado: (2020)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
por: McLaughlin, Taryn, et al.
Publicado: (2023)

Tesamorelin: A hope for ART-induced lipodystrophy
por: Patel, Akash, et al.
Publicado: (2011)

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
por: Bedimo, Roger
Publicado: (2011)

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
por: Fourman, Lindsay T., et al.
Publicado: (2020)

Comparison of Dorsocervical With Abdominal Subcutaneous Adipose Tissue in Patients With and Without Antiretroviral Therapy–Associated Lipodystrophy
por: Sevastianova, Ksenia, et al.
Publicado: (2011)

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
por: Clemmons, David R., et al.
Publicado: (2017)

Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation: An observational cohort study
por: Chen, Song, et al.
Publicado: (2019)

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
por: Fourman, Lindsay T., et al.
Publicado: (2021)

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
por: Mangili, Alexandra, et al.
Publicado: (2015)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Seasonal Antimicrobial Activity of the Airway: Post-Hoc Analysis of a Randomized Placebo-Controlled Double-Blind Trial
por: Vargas Buonfiglio, Luis G., et al.
Publicado: (2020)

Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
por: McLaughlin, Pamela M. J., et al.
Publicado: (2022)

Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials
por: Alev, Levent, et al.
Publicado: (2017)

Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome
por: Kayadjanian, Nathalie, et al.
Publicado: (2021)

Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)
por: Howell, Carol Angela, et al.
Publicado: (2022)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Assessment of direct analgesic effect of duloxetine for chronic low back pain: post hoc path analysis of double-blind, placebo-controlled studies
por: Enomoto, Hiroyuki, et al.
Publicado: (2017)

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
por: Shah, Manish A., et al.
Publicado: (2022)

Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials
por: Hasegawa, Kazuko, et al.
Publicado: (2021)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
por: Costamagna, Isabella, et al.
Publicado: (2021)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Imai, Noboru, et al.
Publicado: (2023)

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes
por: Keymeulen, Bart, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients
por: Murakami, Masato, et al.
Publicado: (2015)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials
por: Nomoto, Masahiro, et al.
Publicado: (2017)

Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double‐blind placebo‐controlled trial
por: Busetto, Gian Maria, et al.
Publicado: (2020)

Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial
por: Tønnesen, Philip, et al.
Publicado: (2022)

Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial
por: Santos, Glenn-Milo, et al.
Publicado: (2021)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study
por: Devlin, John W, et al.
Publicado: (2011)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
por: Sauder, Colin, et al.
Publicado: (2022)

A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials
por: Moore, Angela Yen, et al.
Publicado: (2023)

Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults
por: Kemppinen, Anu, et al.
Publicado: (2020)

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
por: Wang, De‐shen, et al.
Publicado: (2019)

PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia
por: Craig, Colleen M, et al.
Publicado: (2021)

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
por: Andrews, J Scott, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_47epqaeageftkciisgvhtufi5k